Trial Profile
Phase II Clinical Trial Evaluating Intravenous AZD9150 (Antisense STAT3) With MEDI4736 (Anti-PD-L1) in Patients With Advanced Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Danvatirsen (Primary) ; Durvalumab (Primary)
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors AstraZeneca
- 22 Feb 2024 Planned End Date changed from 30 Apr 2024 to 30 Apr 2025.
- 22 Feb 2024 Planned primary completion date changed from 30 Apr 2024 to 30 Apr 2025.
- 13 Mar 2023 Planned End Date changed from 31 Mar 2023 to 30 Apr 2024.